SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology
暂无分享,去创建一个
M. Plebani | A. Doria | C. Cosma | R. Ramonda | A. Padoan | A. Ortolan | M. Lorenzin | G. Cozzi
[1] Shigui Yang,et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): A systematic review and meta-analysis , 2021, International Journal of Infectious Diseases.
[2] A. Khosroshahi,et al. Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population , 2021, Clinical Rheumatology.
[3] Marc-André Langlois,et al. Humoral Responses and Serological Assays in SARS-CoV-2 Infections , 2020, Frontiers in Immunology.
[4] S. Virani,et al. Elevated interleukin levels are associated with higher severity and mortality in COVID 19 – A systematic review, meta-analysis, and meta-regression , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[5] C. Cordon-Cardo,et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.
[7] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[8] N. Basta,et al. Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2 , 2020, Annals of Internal Medicine.
[9] H. Tahir,et al. COVID-19 and rheumatology: is shielding really necessary? , 2020, British journal of hospital medicine.
[10] Q. Yao,et al. COVID-19 in rheumatic disease patients on immunosuppressive agents , 2020, Seminars in Arthritis and Rheumatism.
[11] A. Vaglio,et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases , 2020, Autoimmunity Reviews.
[12] Thomas Henry,et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions , 2020, Autoimmunity Reviews.
[13] F. Ferro,et al. Are patients with systemic lupus erythematosus more prone to result false-positive for SARS-CoV2 serology? , 2020, Clinical and experimental rheumatology.
[14] Jun Yuan,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[15] Mario Plebani,et al. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics , 2020, Clinical chemistry and laboratory medicine.
[16] C. Montecucco,et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies , 2020, Annals of the Rheumatic Diseases.
[17] Dandan Wu,et al. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib , 2020, Journal of Microbiology, Immunology and Infection.
[18] Lei Liu,et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome , 2020, medRxiv.
[19] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[20] P. Tak,et al. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? , 2012, Current opinion in rheumatology.
[21] B. Amor,et al. The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress , 2010, Annals of the rheumatic diseases.
[22] M. Dougados,et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection , 2009, Annals of the rheumatic diseases.